APRE Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 24.1%, SMA50 7.39%, SMA200 -35.52%). The stock’s 14-day RSI is 59.25 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.46% below its high and over 60.6% above its low. Average 10-day trading volume of 153.93 thousand shares is below the 3-month average of 527.57 thousand, indicating normal recent market interest.

Aprea Therapeutics, Inc. has 11.45 million shares outstanding. The public float is 8.78 million shares, elevated short interest at 5.93% of float. This equals 640.35 thousand shares. The short ratio is 1.16 days. Institutional investors hold 32.78% of the float. Insiders own 21.66%. KDev Investments AB holds 1.99 million shares, Redmile Group, LLC has 1.77 million shares and Versant Vantage I, L.P. has 333.33 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Aprea Therapeutics, Inc. generated EPS of -$2.14 over the past year. Five-year average earnings growth is 52.12%. Wall Street analysts project EPS growth of 29.22% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.39. Next year's EPS is expected at $35.54. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $1.20. The high target offers 2400.0% upside. The low target suggests 50.0% downside. The mean target is $8.64. This offers 980.0% upside. Aprea Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 16, 2026, missed forecasts by -15.79%. The prior quarter beat by 327.27%. Over the last six quarters, Apple has recorded several small beats. These include -13.51% in November 07, 2024.

Aprea Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.11. This means the shares are trading below this model’s fair value.

Aprea Therapeutics, Inc. (NASDAQ:APRE) closed at $0.82 USD, gaining $0.02 (2.26%) from the previous close of $0.80. The stock is currently mid-range between its 52-week high and low $0.55 and $2.22. With a market capitalization of about $5.31 million, Aprea Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.57). Key stats such as the average daily volume over the past year has been around 465.51 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Aprea Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Oren Gilad, the company employs approximately 8 people and listed since October 03, 2019. Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways.

Our AI price prediction model suggests that Aprea Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.01%, with price expected at $0.88 by May 14, 2026, within a range of $0.80 to $0.97 3-Month Outlook: Projected rise of 83.77%, reaching $1.47 by July 29, 2026, with a range of $1.29 to $1.59. 1-Year Outlook: Projected loss of -78.75%, with price at $0.17 by April 30, 2027, within a range of $0.00 to $0.36.

Aprea Therapeutics, Inc. (NASDAQ:APRE) shares are flat 2.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aprea Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.24, suggesting 2305.3% upside. Our AI forecast model points to short-term strength (10.01% over two weeks), a medium-term rise (83.77% over three months), and a longer-term loss (-78.75% over one year), with expected trading ranges indicating moderate volatility.

Aprea Therapeutics, Inc. trades at a P/E ratio of -0.49, slightly below the S&P 500 average, with a price-to-sales ratio of 18.19 and a price-to-book ratio of 0.47 suggesting the stock is closer to book value. The P/FCF stands at -0.4, also below market averages.